
Annual report 2024
added 02-14-2025
Kiromic BioPharma Net Debt 2011-2026 | KRBP
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Kiromic BioPharma
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -224 K | -1.66 M | 1.48 M | - | -10.2 K | -1.93 M | -384 K | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.48 M | -1.93 M | -454 K |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
457 M | $ 21.66 | 1.14 % | $ 1.01 B | ||
|
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Aptorum Group Limited
APM
|
-2.77 M | $ 0.9 | -0.2 % | $ 6.62 M | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
2.27 M | - | 2.54 % | $ 160 B | ||
|
ACADIA Pharmaceuticals
ACAD
|
-83 M | $ 22.33 | 1.66 % | $ 3.7 B | ||
|
Esperion Therapeutics
ESPR
|
-165 M | $ 1.94 | 1.31 % | $ 403 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | ||
|
Galectin Therapeutics
GALT
|
-25.6 M | $ 2.38 | 2.33 % | $ 152 M | ||
|
AIkido Pharma
AIKI
|
-31.2 M | - | 1.93 % | $ 17.4 M | ||
|
Greenwich LifeSciences
GLSI
|
-28.7 K | $ 24.07 | -0.58 % | $ 313 M | ||
|
Heron Therapeutics
HRTX
|
-7.17 M | $ 1.18 | -0.84 % | $ 197 M | ||
|
ImmuCell Corporation
ICCC
|
3.77 M | $ 8.26 | -1.07 % | $ 74.6 M | ||
|
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | ||
|
InflaRx N.V.
IFRX
|
-32.3 M | $ 1.61 | 8.78 % | $ 152 M | ||
|
Allakos
ALLK
|
-25 M | - | - | $ 28.6 M | ||
|
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-12 M | - | -11.43 % | $ 502 K | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
Innate Pharma S.A.
IPHA
|
-120 M | $ 1.39 | 0.72 % | $ 235 M | ||
|
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | ||
|
Inventiva S.A.
IVA
|
-95.6 M | $ 5.11 | -0.78 % | $ 138 M | ||
|
Jaguar Health
JAGX
|
116 K | $ 0.29 | -25.25 % | $ 676 K | ||
|
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
533 K | - | -2.5 % | $ 5.88 M | ||
|
Applied Therapeutics
APLT
|
-49.4 M | - | - | $ 8.42 M | ||
|
Aptinyx
APTX
|
-33.8 M | - | -39.0 % | $ 4.57 M | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
Aravive
ARAV
|
-49.6 M | - | -13.39 % | $ 1.45 M | ||
|
Aridis Pharmaceuticals
ARDS
|
-3.05 M | - | 17.91 % | $ 11.1 M | ||
|
KalVista Pharmaceuticals
KALV
|
-55.5 M | $ 19.09 | -2.75 % | $ 1.03 B | ||
|
BioNTech SE
BNTX
|
-973 M | $ 102.36 | -2.94 % | $ 27.2 B | ||
|
Avenue Therapeutics
ATXI
|
-3.13 K | - | -52.27 % | $ 4.45 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | ||
|
Aquestive Therapeutics
AQST
|
-75.5 M | $ 4.11 | 0.61 % | $ 439 M | ||
|
Arcutis Biotherapeutics
ARQT
|
65.3 M | $ 23.18 | -0.34 % | $ 2.95 B | ||
|
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M | ||
|
Autolus Therapeutics plc
AUTL
|
-32.7 M | $ 1.43 | -0.7 % | $ 381 M | ||
|
Aptose Biosciences
APTO
|
-5.53 M | - | -45.71 % | $ 1.2 M | ||
|
AstraZeneca PLC
AZN
|
9.86 B | - | - | $ 96.9 B | ||
|
Ligand Pharmaceuticals Incorporated
LGND
|
-71 M | $ 240.72 | 4.09 % | $ 4.4 B | ||
|
AVROBIO
AVRO
|
-76.6 M | - | 1083.1 % | $ 745 M | ||
|
Eli Lilly and Company
LLY
|
33.8 B | $ 874.81 | -1.06 % | $ 785 B | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-3.5 M | $ 2.9 | -0.34 % | $ 4.77 M | ||
|
BioDelivery Sciences International
BDSI
|
-33.1 M | - | -4.8 % | $ 255 M |